P22082-05/BOSTON

Please enable JavaScript in your browser to complete this form.
What is the most diagnosed leukemia in the US?
On average, what percentage of patients with CLL/SLL need treatment upon diagnosis?
What is the least common upfront treatment option for CLL/SLL?
A 70-year-old patient with CLL is very fearful about COVID-19 and would prefer to avoid time in the hospital; however, says she would be okay with it for short periods, if necessary. Which of these regimens would you recommend?
A 67-year-old patient with CLL and a TP53 mutation prefers a fixed-duration regimen. Which of the following would you recommend?
A young, fit, patient with CLL with high tumor burden is going to start on a fixed-duration ibrutinib + venetoclax regimen. What AE will you be most concerned about in the beginning of therapy?
A Black patient with CLL and TP53 mutation is starting acalabrutinib and obinutuzumab in the next few days. Which of these AEs would you counsel him to monitor for?
A Black patient newly diagnosed with CLL is feeling unsure about whether to pick a fixed- or continuous-duration regimen. She want your advice. How would you approach her in a way that she feels comfortable with the decision?
When trying to build trust with a patient, what is one of the most important things you can do?

Post Test From Live Meeting

Boston Post-Assessment (P22082-05)
Please enable JavaScript in your browser to complete this form.
A 70-year-old patient with CLL is very fearful about COVID-19 and would prefer to avoid time in the hospital; however, says she would be okay with it for short periods, if necessary. Which of these regimens would you recommend?
A 67-year-old patient with CLL and a TP53 mutation prefers a fixed-duration regimen. Which of the following would you recommend?
A young, fit, patient with CLL with high tumor burden is going to start on a fixed-duration ibrutinib + venetoclax regimen. What AE will you be most concerned about in the beginning of therapy?
A Black patient with CLL and TP53 mutation is starting acalabrutinib and obinutuzumab in the next few days. Which of these AEs would you counsel him to monitor for?
A Black patient newly diagnosed with CLL is feeling unsure about whether to pick a fixed- or continuous-duration regimen. She want your advice. How would you approach her in a way that she feels comfortable with the decision?
When trying to build trust with a patient, what is one of the most important things you can do?
Scroll to Top